Sutro Biopharma (STRO) EBT Margin (2017 - 2026)
Sutro Biopharma (STRO) posted EBT Margin of 709.76% for Q4 2025, down 21.0% sequentially from 586.58% in Q3 2025, and down 23648.0% YoY from N/an in Q4 2024.
Powered by 
Analysis
Sutro Biopharma (STRO) EBT Margin (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported EBT Margin for 9 years, with the latest figure at 709.76% in Q4 2025.
- Quarterly EBT Margin fell 23648.0% year-over-year to 709.76% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 187.65% (up 17516.0% YoY) and the FY2025 annual result came in at 186.55%, up 17626.0% from the prior year.
- EBT Margin eased to 709.76% in Q4 2025 per STRO's latest filing, from 586.58% in the prior quarter.
- Over five years, EBT Margin peaked at 41.22% in Q4 2023 and troughed at 709.76% in Q4 2025.
- A 5-year average of 324.23% and a median of 365.69% in 2021 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 52904 bps in 2022, then jumped 44198 bps in 2023.
- Over 5 years, EBT Margin stood at 357.85% in 2021, then slipped by 12 bps to 400.76% in 2022, then jumped by 110 bps to 41.22% in 2023, then tumbled by 1248 bps to 473.28% in 2024, then tumbled by 50 bps to 709.76% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 709.76%, 586.58%, and 18.07% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -2.67% |
| 10 | Sutro Biopharma | 332.59 Mn | 168.25 Mn | - | -391.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -391.63% |
| Dec 31, 2025 | -709.76% |
| Sep 30, 2025 | -586.58% |
| Jun 30, 2025 | -18.07% |
| Mar 31, 2025 | -375.45% |
| Dec 31, 2024 | -473.28% |
| Sep 30, 2024 | -572.62% |
| Jun 30, 2024 | -186.77% |
| Mar 31, 2024 | -447.52% |
| Dec 31, 2023 | 41.22% |
| Sep 30, 2023 | -280.34% |
| Jun 30, 2023 | -368.55% |
| Mar 31, 2023 | -391.79% |
| Dec 31, 2022 | -400.76% |
| Sep 30, 2022 | -77.50% |
| Jun 30, 2022 | -83.68% |
| Mar 31, 2022 | -663.22% |
| Dec 31, 2021 | -357.85% |
| Sep 30, 2021 | -362.83% |
| Jun 30, 2021 | -21.93% |